Novartis | Salg Og Administrasjonskostnader



Selling And Administration Expenses Endring Dato
AbbVie USD 3.86B 306M 2024-12
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Bausch Health Companies USD 850M 18M 2024-09
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Canopy Growth CAD 40.62M 308K 2024-12
Corcept Therapeutics USD 83.37M 9.63M 2024-12
Drreddys Laboratories INR 21.59B 436M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
Glaxosmithkline GBP 2.7B 632M 2024-12
Indivior 133M 11M 2024-09
J&J USD 6.45B 975M 2024-12
Merck USD 2.85B 148M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Pacira USD 79.61M 5.28M 2024-12
Perrigo USD 234.8M 36.7M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Prestige Brands USD 64.13M 3.35M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Sanofi EUR 2.68B 26M 2024-09
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12
Zoetis USD 625M 60M 2024-12



Novartis Salg Og Administrasjonskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.